Thursday July 30, 2026 6:30 AM ET

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

Tuesday July 21, 2026 7:00 AM ET

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

Tuesday July 7, 2026 7:00 AM ET

U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

Monday June 29, 2026 7:00 AM ET

Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET

Saturday June 13, 2026 9:00 AM ET

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Monday June 1, 2026 5:00 AM ET

Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

Friday May 29, 2026 7:00 AM ET

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

Friday May 22, 2026 9:15 AM ET

Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

Tuesday May 12, 2026 9:31 AM ET

Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease

Tuesday May 12, 2026 9:30 AM ET

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

Wednesday April 29, 2026 6:30 AM ET

Agios Reports First Quarter 2026 Financial Results and Provides Business Update

Monday April 6, 2026 7:00 AM ET

Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

Tuesday March 31, 2026 7:00 AM ET

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Monday March 2, 2026 7:00 AM ET

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates